171 related articles for article (PubMed ID: 28549444)
1. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer.
Xu C; Liu Y; Ge X; Jiang D; Zhang Y; Ji Y; Hou J; Huang J; Su J; Zeng H; Qin J; Hou Y
Diagn Pathol; 2017 May; 12(1):41. PubMed ID: 28549444
[TBL] [Abstract][Full Text] [Related]
2. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.
Ahn S; Ahn S; Van Vrancken M; Lee M; Ha SY; Lee H; Min BH; Lee JH; Kim JJ; Choi S; Jung SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kim KM
Oncotarget; 2015 Nov; 6(35):38372-80. PubMed ID: 26460823
[TBL] [Abstract][Full Text] [Related]
3. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.
Huang SC; Ng KF; Lee SE; Chen KH; Yeh TS; Chen TC
Gastric Cancer; 2016 Jan; 19(1):176-82. PubMed ID: 25512144
[TBL] [Abstract][Full Text] [Related]
4. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
[TBL] [Abstract][Full Text] [Related]
5. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer.
Tominaga N; Gotoda T; Hara M; Hale MD; Tsuchiya T; Matsubayashi J; Kono S; Kusano C; Itoi T; Fujimoto K; Moriyasu F; Grabsch HI
Gastric Cancer; 2016 Apr; 19(2):553-560. PubMed ID: 25987463
[TBL] [Abstract][Full Text] [Related]
6. Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma.
Huber AR; Buscaglia B; Koltz BR; Henry J; McMahon L; Guo J; Hicks DG; Whitney-Miller CL
Am J Clin Pathol; 2019 Apr; 151(5):461-468. PubMed ID: 30624589
[TBL] [Abstract][Full Text] [Related]
7. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
8. The age variation of HER2 immunohistochemistry positive rate in biopsy specimens of gastric cancer.
Xi Y; Xu C; Liu Y; Yan X; Huang C; Liu Y; Mei J; Wang Z; Liu B; Li X; Li W; Lan J; Gao P; Wu J; Zheng J; Hou Y
Pathol Res Pract; 2020 Apr; 216(4):152882. PubMed ID: 32113795
[TBL] [Abstract][Full Text] [Related]
9. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
[TBL] [Abstract][Full Text] [Related]
10. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
11. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
Fazlollahi L; Remotti HE; Iuga A; Yang HM; Lagana SM; Sepulveda AR
Arch Pathol Lab Med; 2018 Apr; 142(4):516-522. PubMed ID: 28782986
[TBL] [Abstract][Full Text] [Related]
12. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
13. Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma.
Nergiz D; Alikanoğlu AS; Süren D; Gömceli İ; Öztürk B
Indian J Pathol Microbiol; 2022; 65(2):321-327. PubMed ID: 35435366
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma.
Gonzalez RS; Messing S; Tu X; McMahon LA; Whitney-Miller CL
Hum Pathol; 2016 Oct; 56():16-21. PubMed ID: 27342907
[TBL] [Abstract][Full Text] [Related]
15. HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.
Kumarasinghe MP; Morey A; Bilous M; Farshid G; Francis G; Lampe G; McCue G; Von Neumann-Cosel V; Fox SB
Pathology; 2017 Oct; 49(6):575-581. PubMed ID: 28823752
[TBL] [Abstract][Full Text] [Related]
16. Digital image analysis of HER2 immunohistochemistry in gastric- and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens.
Koopman T; de Bock GH; Buikema HJ; Smits MM; Louwen M; Hage M; Imholz ALT; van der Vegt B
Histopathology; 2018 Jan; 72(2):191-200. PubMed ID: 28746978
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks.
Ge X; Wang H; Zeng H; Jin X; Sujie A; Xu C; Liu Y; Huang J; Ji Y; Tan Y; Liu T; Hou Y; Qin J; Sun Y; Qin X
Hum Pathol; 2015 Jun; 46(6):850-7. PubMed ID: 25863425
[TBL] [Abstract][Full Text] [Related]
18. Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes.
Kochi M; Fujii M; Masuda S; Kanamori N; Mihara Y; Funada T; Tamegai H; Watanabe M; Suda H; Takayama T
Diagn Pathol; 2013 Nov; 8():191. PubMed ID: 24261710
[TBL] [Abstract][Full Text] [Related]
19. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
[TBL] [Abstract][Full Text] [Related]
20. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.
Bozzetti C; Negri FV; Lagrasta CA; Crafa P; Bassano C; Tamagnini I; Gardini G; Nizzoli R; Leonardi F; Gasparro D; Camisa R; Cavalli S; Silini EM; Ardizzoni A
Br J Cancer; 2011 Apr; 104(9):1372-6. PubMed ID: 21487407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]